BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
FABP1
,
T cell differentiation
,
Influenza
,
Pancreas
,
Pharmacogenetics
,
Vitamin E
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
c ret
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP Prostate cancer PC3 cells with gene overexpression perturbations (2 of 2)
L1000 CMAP - Hepatocellular carcinoma Hep G2 cells with shRNA-mediated gene knockdown (1 of 2)
L1000 CMAP Prostate cancer VCaP cells with gene overexpression perturbations
L1000 CMAP Colorectal cancer HT 29 cells with gene overexpression perturbations
Adult and larval C elegans of NEP-1 knockout and wildtype strains
Explore Curated Studies Results
Literature
Most Relevant Literature
Loss-of-function mutation of c-Ret causes cerebellar hypoplasia in mice with Hirschsprung disease an…
Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders.
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both…
Progress and challenges in RET-targeted cancer therapy.
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormaliti…
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor.
A Study of EP0031-101 in Patients With Advanced RET-altered Malignancies
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ